DCGO
DCGO
DocGo Inc.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $70.81M ▼ | $60.1M ▲ | $-27.77M ▼ | -39.22% ▼ | $-0.28 ▼ | $-21.27M ▼ |
| Q2-2025 | $80.42M ▼ | $42.9M ▼ | $-11.16M ▼ | -13.87% ▼ | $-0.11 ▼ | $-13.49M ▼ |
| Q1-2025 | $96.03M ▼ | $44.85M ▼ | $-9.41M ▼ | -9.79% ▼ | $-0.09 ▼ | $-10.62M ▼ |
| Q4-2024 | $120.83M ▼ | $47.97M ▲ | $-3.26M ▼ | -2.7% ▼ | $-0.03 ▼ | $-3.16M ▼ |
| Q3-2024 | $138.68M | $39.78M | $5.5M | 3.96% | $0.05 | $14.31M |
What's going well?
The company received a large tax benefit, which helped soften the blow of bigger losses. R&D spending remains steady, suggesting continued investment in future growth.
What's concerning?
Sales fell sharply while costs jumped, leading to much bigger losses. Margins are shrinking, overhead is high, and share dilution is hurting existing shareholders.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $73.36M ▼ | $353.78M ▼ | $93.12M ▼ | $270.53M ▼ |
| Q2-2025 | $104.16M ▲ | $408.26M ▼ | $120.53M ▼ | $297.28M ▼ |
| Q1-2025 | $79.01M ▼ | $430.79M ▼ | $128.87M ▼ | $309.34M ▼ |
| Q4-2024 | $89.24M ▼ | $455.62M ▼ | $140.44M ▼ | $320.92M ▼ |
| Q3-2024 | $89.46M | $493.88M | $168.98M | $325.21M |
What's financially strong about this company?
The company has much more equity than debt, a healthy current ratio, and paid down a large chunk of debt this quarter. Most assets are liquid, and there are no inventory or deferred revenue risks.
What are the financial risks or weaknesses?
Cash fell by 30% and equity dropped, which could signal operating losses or heavy spending. Retained earnings are negative, showing past losses, and the drop in liquidity is a concern if it continues.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-29.66M ▼ | $1.66M ▼ | $1.1M ▲ | $-33.05M ▼ | $-30.95M ▼ | $101.16K ▼ |
| Q2-2025 | $-13.29M ▼ | $33.6M ▲ | $-21.38M ▼ | $-7.38M ▲ | $5.5M ▲ | $32.04M ▲ |
| Q1-2025 | $-11.08M ▼ | $9.66M ▼ | $-5.73M ▼ | $-8.52M ▼ | $-4.28M ▼ | $7.47M ▼ |
| Q4-2024 | $-7.65M ▼ | $12.89M ▼ | $-5.57M ▼ | $-7.86M ▼ | $-1.24M ▼ | $12.22M ▼ |
| Q3-2024 | $4.55M | $31.03M | $-1.51M | $-7.35M | $22.76M | $29.59M |
What's strong about this company's cash flow?
The company is still generating a small amount of cash from operations and has a decent cash cushion left. Receivables collection improved, bringing in more cash from customers.
What are the cash flow concerns?
Operating and free cash flow collapsed compared to last quarter, and the company burned through $31 million in cash. If this trend continues, the cash balance could become a problem.
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
Mobile Health Services Segment | $90.00M ▲ | $70.00M ▼ | $50.00M ▼ | $30.00M ▼ |
Transportation Services Segment | $50.00M ▲ | $50.00M ▲ | $50.00M ▲ | $50.00M ▲ |
Revenue by Geography
| Region | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
UNITED KINGDOM | $20.00M ▲ | $20.00M ▲ | $10.00M ▼ | $10.00M ▲ |
UNITED STATES | $120.00M ▲ | $110.00M ▼ | $80.00M ▼ | $70.00M ▼ |
Q3 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at DocGo Inc.'s financial evolution and strategic trajectory over the past five years.
Key strengths include a successful transition from losses to ongoing profitability, a strong and generally cash-rich balance sheet with manageable leverage, and a business model that sits at the center of important healthcare trends such as home-based care, virtual visits, and preventative medicine. The integrated technology and field operations platform, combined with a growing track record of reducing unnecessary hospital visits, provides a compelling value proposition to payers and health systems. Recent recovery in both earnings and cash flow shows that management can adjust operations when conditions become challenging.
Major risks revolve around growth durability, margin stability, and competitive dynamics. Revenue growth has recently stalled after a rapid ramp-up, raising the possibility that some of the earlier momentum was driven by temporary factors or easy wins. Margins are modest and vulnerable to rising labor costs, contract repricing, and overhead growth. Heavy reliance on contracts with institutional customers introduces renewal and concentration risks, while the elevated level of goodwill and intangibles adds the possibility of future impairments. Regulatory changes and competition from large health systems, insurers, and technology firms could further pressure both growth and profitability.
The forward picture for DocGo is balanced. On one hand, it operates in a structurally attractive niche—technology-enabled, out-of-hospital care—that aligns with payer and patient preferences for lower-cost, more convenient services. Its improved profitability, stronger recent cash generation, and negative net debt position give it room to invest and adapt. On the other hand, the company now faces the harder task of sustaining growth and scaling efficiently in a more competitive, normalized environment. Future performance will likely hinge on its ability to reignite top-line growth, convert innovation spending into distinctive offerings, keep working capital and costs under control, and deepen long-term partnerships with key healthcare stakeholders.
About DocGo Inc.
https://www.docgo.comDocGo, Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $70.81M ▼ | $60.1M ▲ | $-27.77M ▼ | -39.22% ▼ | $-0.28 ▼ | $-21.27M ▼ |
| Q2-2025 | $80.42M ▼ | $42.9M ▼ | $-11.16M ▼ | -13.87% ▼ | $-0.11 ▼ | $-13.49M ▼ |
| Q1-2025 | $96.03M ▼ | $44.85M ▼ | $-9.41M ▼ | -9.79% ▼ | $-0.09 ▼ | $-10.62M ▼ |
| Q4-2024 | $120.83M ▼ | $47.97M ▲ | $-3.26M ▼ | -2.7% ▼ | $-0.03 ▼ | $-3.16M ▼ |
| Q3-2024 | $138.68M | $39.78M | $5.5M | 3.96% | $0.05 | $14.31M |
What's going well?
The company received a large tax benefit, which helped soften the blow of bigger losses. R&D spending remains steady, suggesting continued investment in future growth.
What's concerning?
Sales fell sharply while costs jumped, leading to much bigger losses. Margins are shrinking, overhead is high, and share dilution is hurting existing shareholders.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $73.36M ▼ | $353.78M ▼ | $93.12M ▼ | $270.53M ▼ |
| Q2-2025 | $104.16M ▲ | $408.26M ▼ | $120.53M ▼ | $297.28M ▼ |
| Q1-2025 | $79.01M ▼ | $430.79M ▼ | $128.87M ▼ | $309.34M ▼ |
| Q4-2024 | $89.24M ▼ | $455.62M ▼ | $140.44M ▼ | $320.92M ▼ |
| Q3-2024 | $89.46M | $493.88M | $168.98M | $325.21M |
What's financially strong about this company?
The company has much more equity than debt, a healthy current ratio, and paid down a large chunk of debt this quarter. Most assets are liquid, and there are no inventory or deferred revenue risks.
What are the financial risks or weaknesses?
Cash fell by 30% and equity dropped, which could signal operating losses or heavy spending. Retained earnings are negative, showing past losses, and the drop in liquidity is a concern if it continues.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-29.66M ▼ | $1.66M ▼ | $1.1M ▲ | $-33.05M ▼ | $-30.95M ▼ | $101.16K ▼ |
| Q2-2025 | $-13.29M ▼ | $33.6M ▲ | $-21.38M ▼ | $-7.38M ▲ | $5.5M ▲ | $32.04M ▲ |
| Q1-2025 | $-11.08M ▼ | $9.66M ▼ | $-5.73M ▼ | $-8.52M ▼ | $-4.28M ▼ | $7.47M ▼ |
| Q4-2024 | $-7.65M ▼ | $12.89M ▼ | $-5.57M ▼ | $-7.86M ▼ | $-1.24M ▼ | $12.22M ▼ |
| Q3-2024 | $4.55M | $31.03M | $-1.51M | $-7.35M | $22.76M | $29.59M |
What's strong about this company's cash flow?
The company is still generating a small amount of cash from operations and has a decent cash cushion left. Receivables collection improved, bringing in more cash from customers.
What are the cash flow concerns?
Operating and free cash flow collapsed compared to last quarter, and the company burned through $31 million in cash. If this trend continues, the cash balance could become a problem.
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
Mobile Health Services Segment | $90.00M ▲ | $70.00M ▼ | $50.00M ▼ | $30.00M ▼ |
Transportation Services Segment | $50.00M ▲ | $50.00M ▲ | $50.00M ▲ | $50.00M ▲ |
Revenue by Geography
| Region | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
UNITED KINGDOM | $20.00M ▲ | $20.00M ▲ | $10.00M ▼ | $10.00M ▲ |
UNITED STATES | $120.00M ▲ | $110.00M ▼ | $80.00M ▼ | $70.00M ▼ |
Q3 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at DocGo Inc.'s financial evolution and strategic trajectory over the past five years.
Key strengths include a successful transition from losses to ongoing profitability, a strong and generally cash-rich balance sheet with manageable leverage, and a business model that sits at the center of important healthcare trends such as home-based care, virtual visits, and preventative medicine. The integrated technology and field operations platform, combined with a growing track record of reducing unnecessary hospital visits, provides a compelling value proposition to payers and health systems. Recent recovery in both earnings and cash flow shows that management can adjust operations when conditions become challenging.
Major risks revolve around growth durability, margin stability, and competitive dynamics. Revenue growth has recently stalled after a rapid ramp-up, raising the possibility that some of the earlier momentum was driven by temporary factors or easy wins. Margins are modest and vulnerable to rising labor costs, contract repricing, and overhead growth. Heavy reliance on contracts with institutional customers introduces renewal and concentration risks, while the elevated level of goodwill and intangibles adds the possibility of future impairments. Regulatory changes and competition from large health systems, insurers, and technology firms could further pressure both growth and profitability.
The forward picture for DocGo is balanced. On one hand, it operates in a structurally attractive niche—technology-enabled, out-of-hospital care—that aligns with payer and patient preferences for lower-cost, more convenient services. Its improved profitability, stronger recent cash generation, and negative net debt position give it room to invest and adapt. On the other hand, the company now faces the harder task of sustaining growth and scaling efficiently in a more competitive, normalized environment. Future performance will likely hinge on its ability to reignite top-line growth, convert innovation spending into distinctive offerings, keep working capital and costs under control, and deepen long-term partnerships with key healthcare stakeholders.

CEO
Lee Bienstock
Compensation Summary
(Year 2023)
Upcoming Earnings
ETFs Holding This Stock
Summary
Showing Top 3 of 52
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:7.04M
Value:$4.82M
BLACKROCK, INC.
Shares:6.43M
Value:$4.4M
VANGUARD GROUP INC
Shares:5.09M
Value:$3.49M
Summary
Showing Top 3 of 142

